Carisma Therapeutics Announces Adjournment of Annual Meeting of Shareholders – June 13, 2024

The meeting will resume on Friday, June 14, 2024 at 10:00 a.m. Eastern Time.

PHILADELPHIA, June 13, 2024 /PRNewswire/ — Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative immunotherapies, today announced that the Company’s virtual annual meeting of shareholders , held on June 13, 2024, had been convened and adjourned. , without any activity being carried out, due to technical difficulties with the third-party hosting site. The meeting will resume at 10:00 a.m. Eastern Time on Friday, June 14, 2024.

Carisma shareholders will be able to attend the virtual annual meeting online, vote their shares electronically and submit questions via the Internet by virtual audio conference at https://meetnow.global/MAJJ4AY.

About Carisma

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on using our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a proprietary, comprehensive, differentiated cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in the innate and adaptive immune response. Carisma is headquartered in Philadelphia, Pennsylvania. For more information, please visit www.carismatx.com.

Media Contact:
Julia Stern
(763) 350-5223
[email protected]

Investors:
Shveta Dighé
Head of Investor Relations
[email protected]

View original content to download multimedia: https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-adjournment-of-annual-meeting-of-stockholders-302172413.html

SOURCE Carisma Therapeutics Inc.

Company codes: NASDAQ-NMS:CARM